Human derived monocyte attracting purified peptide products useful in a method of treating infection and neoplasms in a human body
US6090795A · kind A · utility
8Cited by
4References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 15, 1991 |
| Grant date | Jul 18, 2000 |
| Priority date | — |
| Expiry date | Apr 15, 2011 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. Methods of treating infection and neoplasms in a human body with the peptide products are additionally provided, as well as pharmaceutical compositions for the peptide products.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.